Changes of faecal microbiota in patients with Crohn's disease treated with an elemental diet and total parenteral nutrition

Digestive and Liver Disease

Volumn 44, Issue 9, 2012, Pages 736-742

  Shiga, Hisashi ^a   Kajiura, Takayuki ^b   Shinozaki, Junko ^b   Takagi, Sho ^a   Kinouchi, Yoshitaka ^a   Takahashi, Seiichi ^a   Negoro, Kenichi ^a   Endo, Katsuya ^a   Kakuta, Yoichi ^a   Suzuki, Manabu ^b   Shimosegawa, Tooru ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AJINOMOTO CO INC   (Japan)

Author keywords

Crohn's disease; Elemental diet; Intestinal microbiota; T RFLP

Indexed keywords

BACTERIAL DNA; DNA 16S;

ADULT; AGED; ARTICLE; BACTEROIDES FRAGILIS; BIFIDOBACTERIUM; CLINICAL ARTICLE; CLOSTRIDIUM; CONTROLLED STUDY; CROHN DISEASE; ELEMENTAL DIET; ENTEROCOCCUS; ESCHERICHIA COLI; FECES ANALYSIS; FECES MICROFLORA; FEMALE; HUMAN; LACTOBACILLUS; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TOTAL PARENTERAL NUTRITION;

ADOLESCENT; ADULT; AGED; BACTEROIDES FRAGILIS; BIFIDOBACTERIUM; CASE-CONTROL STUDIES; CLOSTRIDIUM; CROHN DISEASE; DNA, BACTERIAL; ENTEROCOCCUS; FECES; FEMALE; FOOD, FORMULATED; HUMANS; MALE; METAGENOME; MIDDLE AGED; PARENTERAL NUTRITION, TOTAL; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REAL-TIME POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84864410080     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.04.014     Document Type: Article

References (56)

1. Khor B., Gardet A., Xavier R.J. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011, 474:307-317.
2. Kaser A., Zeissig S., Blumberg R.S. Inflammatory bowel disease. Annual Review of Immunology 2010, 28:573-621.
3. Chassaing B., Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011, 140:1720-1728.
4. Elson C.O., Cong Y., McCracken V.J., et al. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunological Reviews 2005, 206:260-276.
5. Sartor R.B. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004, 126:1620-1633.
6. Landers C.J., Cohavy O., Misra R., et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002, 123:689-699.
7. Mow W.S., Vasiliauskas E.A., Lin Y.C., et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004, 126:414-424.
8. Quinton J.F., Sendid B., Reumaux D., et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998, 42:788-791.
9. Sutton C.L., Kim J., Yamane A., et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology 2000, 119:23-31.
10. Swidsinski A., Weber J., Loening-Baucke V., et al. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. Journal of Clinical Microbiology 2005, 43:3380-3389.
11. Barnich N., Darfeuille-Michaud A. Adherent-invasive Escherichia coli and Crohn's disease. Current Opinion in Gastroenterology 2007, 23:16-20.
12. Feller M., Huwiler K., Schoepfer A., et al. Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clinical Infectious Diseases 2010, 50:473-480.
13. Rahimi R., Nikfar S., Rezaie A., et al. A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease. Clinical Therapeutics 2006, 28:1983-1988.
14. Karimi O., Pena A.S., Probiotics van Bodegraven A.A. (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot study. Drugs Today 2005, 41:453-459.
15. Berni Canani R., Terrin G., Borrelli O., et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Digestive and Liver Disease 2005, 38:381-387.
16. Gorard D.A., Hunt J.B., Payne-James J.J., et al. Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone. Gut 1993, 34:1198-1202.
17. Papadopoulou A., Rawashdeh M.O., Brown G.A., et al. Remission following an elemental diet or prednisolone in Crohn's disease. Acta Paediatrica 1995, 84:79-83.
18. Okada M., Yao T., Yamamoto T., et al. Controlled trial comparing an elemental diet with prednisolone in the treatment of active Crohn's disease. Hepato-Gastroenterology 1990, 37:72-80.
19. O'Moráin C., Segal A.W., Levi A.J. Elemental diet as primary treatment of acute Crohn's disease: a controlled trial. British Medical Journal (Clinical Research Edition) 1984, 288:1859-1862.
20. Bamba T., Shimoyama T., Sasaki M., et al. Dietary fat attenuates the benefits of an elemental diet in active Crohn's disease: a randomized, controlled trial. European Journal of Gastroenterology and Hepatology 2003, 15:151-157.
21. Yamamoto T., Nakahigashi M., Umegae S., et al. Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflammatory Bowel Diseases 2005, 11:580-588.
22. Fischer J.E., Foster G.S., Abel R.M., et al. Hyperalimentation as primary therapy for inflammatory bowel disease. American Journal of Surgery 1973, 125:165-175.
23. Fuchigami T., Ohgushi H., Imamura K., et al. Effects of total parenteral nutrition on colonic lesions in Crohn's disease: radiographic and endoscopic study. Gastroenterologia Japonica 1982, 17:521-529.
24. Ostro M.J., Greenberg G.R., Jeejeebhoy K.N. Total parenteral nutrition and complete bowel rest in the management of Crohn's disease. Journal of Parenteral and Enteral Nutrition 1985, 9:280-287.
25. Greenberg G.R., Fleming C.R., Jeejeebhoy K.N., et al. Controlled trial of bowel rest and nutritional support in the management of Crohn's disease. Gut 1988, 29:1309-1315.
26. Matsuki T., Watanabe K., Fujimoto J., et al. Use of 16 S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in human feces. Applied and Environment Microbiology 2004, 70:7220-7228.
27. Kibe R., Sakamoto M., Hayashi H., et al. Maturation of the murine cecal microbiota as revealed by terminal restriction fragment length polymorphism and 16 S rRNA gene clone libraries. FEMS Microbiology Letters 2004, 235:139-146.
28. Sakamoto M., Hayashi H., Benno Y. Terminal restriction fragment length polymorphism analysis for human fecal microbiota and its application for analysis of complex bifidobacterial communities. Microbiology and Immunology 2003, 47:133-142.
29. Matsumoto M., Sakamoto M., Hayashi H., et al. Novel phylogenetic assignment database for terminal-restriction fragment length polymorphism analysis of human colonic microbiota. Journal of Microbiological Methods 2005, 61:305-319.
30. Qin J., Li R., Raes J., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65.
31. Andoh A., Imaeda H., Aomatsu T., et al. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. Journal of Gastroenterology 2011, 46:479-486.
32. Manichanh C., Rigottier-Gois L., Bonnaud E., et al. Reduced diversity of fecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006, 55:205-211.
33. Sokol H., Seksik P., Rigottier-Gois L., et al. Specificities of the fecal microbiota in inflammatory bowel disease. Inflammatory Bowel Diseases 2006, 12:106-111.
34. Takaishi H., Matsuki T., Nakazawa A., et al. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. International Journal of Medical Microbiology 2008, 298:463-472.
35. Sokol H., Pigneur B., Watterlot L., et al. Fecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn's disease patients. Proceedings of the National Academy of Sciences 2008, 105:16731-16736.
36. Sokol H., Seksik P., Furet J.P., et al. Low counts of Fecalibacterium prausnitzii in colitis microbiota. Inflammatory Bowel Diseases 2009, 15:1183-1189.
37. Kang S., Denman S.E., Morrison M., et al. Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray. Inflammatory Bowel Diseases 2010, 16:2034-2042.
38. Mondot S., Kang S., Furet J.P., et al. Highlighting new phylogenetic specificities of Crohn's disease microbiota. Inflammatory Bowel Diseases 2011, 17:185-192.
39. Martinez-Medina M., Aldeguer X., Lopez-Siles M., et al. Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E coli (AIEC) in Crohn's disease. Inflammatory Bowel Diseases 2009, 15:872-882.
40. Isenmann R., Schwarz M., Rozdzinski E., et al. Interaction of fibronectin and aggregation substance promotes adherence of Enterococcus fecalis to human colon. Digestive Diseases and Sciences 2002, 47:462-468.
41. Marcinkiewicz J., Ciszek M., Bobek M., et al. Differential inflammatory mediator response in vitro from murine macrophages to lactobacilli and pathogenic intestinal bacteria. International Journal of Experimental Pathology 2007, 88:155-164.
42. Bengmark S., Jeppsson B. Gastrointestinal surface protection and mucosa reconditioning. Journal of Parenteral and Entera Nutrition 1995, 19:410-415.
43. Salminen S., Isolauri E., Onnela T. Gut flora in normal and disordered states. Chemotherapy 1995, 41:5-15.
44. Walker A.W., Sanderson J.D., Churcher C., et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiology 2011, 10:11-17.
45. Whelan K., Judd P.A., Preedy V.R., et al. Enteral feeding: the effect on fecal output, the fecal microflora and SCFA concentrations. Proceedings of the Nutrition Society 2004, 63:105-113.
46. Kajiura T., Takeda T., Sakata S., et al. Change of intestinal microbiota with elemental diet and its impact on therapeutic effects in a murine model of chronic colitis. Digestive Diseases and Sciences 2009, 54:1892-1900.
47. Pimentel M., Constantino T., Kong Y., et al. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Digestive Diseases and Sciences 2004, 49:73-77.
48. Andoh A., Tsujikawa T., Sasaki M., et al. Fecal microbiota profile of Crohn's disease determined by terminal restriction fragment length polymorphism analysis. Alimentary Pharmacology and Therapeutics 2009, 29:75-82.
49. Kishi D., Takahashi I., Kai Y., et al. Alteration of V beta usage and cytokine production of CD4+ TCR beta beta homodimer T cells by elimination of Bacteroides vulgatus prevents colitis in TCR alpha-chain-deficient mice. Journal of Immunology 2000, 165:5891-5899.
50. Lopez-Marti M.G., Jhaveri R. Bacteremia caused by an Enterococcus fecalis isolate with high-level linezolid resistance in a teenager with Crohn's disease. Pediatric Infectious Disease Journal 2009, 28:663-664.
51. Berkelhammer C., Andrejic J., Mohammed A. Endocarditis in Crohn's disease. Inflammatory Bowel Diseases 2009, 15:1293-1294.
52. Jones V.A. Comparison of total parenteral nutrition and elemental diet in induction of remission of Crohn's disease. Long-term maintenance of remission by personalized food exclusion diets. Digestive Diseases and Sciences 1987, 32:S100-S107.
53. Moran A. Bowel rest and elemental diet in Crohn's disease. Gastroenterology 1993, 104:1238-1239.
54. O'Sullivan M.A., O'Morain C.A. Nutritional therapy in Crohn's disease. Inflammatory Bowel Diseases 1998, 4:45-53.
55. Andou A., Hisamatsu T., Okamoto S., et al. Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokine production from macrophages. Gastroenterology 2009, 136:564-574.
56. Takagi S., Utsunomiya K., Kuriyama S., et al. Quality of life of patients and medical cost of half elemental diet as maintenance therapy for Crohn's disease: secondary outcomes of a randomised controlled trial. Digestive and Liver Disease 2009, 41:390-394.